This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
, No Gclids
Disease Info Card
Oncogenic Osteomalacia
Information about Oncogenic Osteomalacia: characteristics, related genes and pathways, plus antibodies you can use for research. This page is being enriched constantly, if you see some information you would like this page to include please send your suggestions to us.
Overview of Oncogenic Osteomalacia
Most recent studies have shown that Oncogenic Osteomalacia shares some biological mechanisms with bone-neoplasms, familial-hypophosphatemia, familial-hypophosphatemic-bone-disease, fracture, hemangiopericytoma, hypophosphatemia, hypophosphatemic-rickets, mesenchymal-cell-neoplasm, mesenchymoma, muscle-weakness, neoplasms, osteomalacia, pain, paraneoplastic-syndromes, phosphate-diabetes, phosphaturic-mesenchymal-tumor, rickets, soft-tissue-neoplasms, weakness.
Among the many pathways, these few ones have gauged particular interests from scientists studying Oncogenic Osteomalacia, and have been seen in publications frequently: Aging, Alanine Transport, Bone Mineralization, Bone Remodeling, Bone Resorption, Cell Proliferation, Excretion, Glomerular Filtration, Hormone Secretion, Intestinal Absorption, Ion Homeostasis, Ion Transport, Localization, Ossification, Pathogenesis, Regulation Of Phosphate Transport, Renal Phosphate Excretion, Secretion, Sodium-dependent Phosphate Transport, Transport
Quite a number of genes have been found to play important roles in Oncogenic Osteomalacia, such as AVPR2, BEST1, BGLAP, CALCA, DMD, DMP1, FGF23, FGF7, GSTP1, MEPE, PHEX, PTH, PTHLH, PTRH1, RAPGEF5, SERPINA1, SFRP4, SLC34A1, SST. See what Boster has to offer for the research of these genes by clicking the gene name links below and view a more detailed info card/product listing for that gene.
In a later update, we will include information such as current drugs and therapy solutions as well as on-going and past clinical trials for this disease. Plesae stay updated.